Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA's Throckmorton Says There Is No "Systematic Conservatism" On Diabetes Drugs

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Based on the number of investigational new drug applications submitted and meetings requested with FDA, the agency's requirements for studying the cardiovascular safety of diabetes drugs have not had a dramatically negative effect on innovation, despite “allegations” to the contrary, asserted the agency’s deputy director Douglas Throckmorton at the American Diabetes Association meeting.

You may also be interested in...

Cardio Safety: Does FDA Expect More From Obesity Than Diabetes Products?

VCs Think Twice About Type 2 Diabetes Investments

Venture capitalists are reevaluating type 2 diabetes investments in light of daunting new regulatory hurdles and an economic climate that limits their ability to cash out of such companies in a timely fashion. But, say some VCs, truly innovative compounds may be worth the bigger R&D bills and longer time to exit given the dazzlingly large market at stake

FDA Diabetes Guidance Encourages Enrollment Of Sicker Patients

In raising pre-market safety standards, FDA says that development time will not necessarily increase if a robust protocol is used.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts